Four-Part Case Series: Treatment Challenges in Schizophrenia – Q&A Session 2
neuroscienceCME WebcastPremiere Date: Thursday, July 13, 2017
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, July 13, 2018
Note: Credit Is No Longer Available
|John M. Kane, MD
Senior Vice President for Behavioral Health Services
New Hyde Park, NY
Professor and Chair, Department of Psychiatry
Hofstra Northwell School of Medicine
The positive symptoms of schizophrenia, such as hallucinations, delusions, and aggressive symptoms, receive the most clinical attention and are the primary targets for pharmacological treatment. Unfortunately, it is the negative and cognitive symptoms that persist longer than positive symptoms, are more difficult to treat, and contribute to chronicity and disability.1
The newer treatments that have become available are better tolerated with improved side-effect profiles and may have an important role in improving social functioning. There has been an unmet need for better tolerated antipsychotics with broad-based symptom control that improve patient functioning. Recently, FDA-approved agents that offer partial D2 receptor agonism and have other unique properties that may affect the clinical profile offer the possibility of improved symptom management and reduced adverse effects.
In this CME Outfitters patient case and expert consult Q & A session, faculty will go in-depth with the case study answering your questions while offering evidence, guidelines, and quality measures to improve the long term management of patients with schizophrenia.
Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Update on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatr Dis Treat. 2016;12:1837-1842.
At the end of this CE activity, participants should be able to:
- Evaluate the efficacy and safety profiles of recent FDA-approved agents to treat schizophrenia for inclusion into appropriate treatment plans.
- Incorporate into practice the latest advances in the management of schizophrenia.
Supported by an educational grant from Allergan.
Psychiatrists, pharmacists, and other members of the interprofessional team caring for individuals with schizophrenia.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .75 contact hours (0.075 CEUs) Universal Activity Number:
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kane has disclosed that he receives grant support from Janssen Pharmaceuticals Inc. and Otsuka. He serves on the advisory board for Alkermes; Intra-Cellular Therapies, Inc.; Lundbeck; Neurocrine Biosciences Inc.; Otsuka America Pharmaceutical, Inc.; Pierre Fabre; Takeda Pharmaceuticals U.S.A., Inc.; and Teva. He serves as a consultant for Alkermes; Allergan; Eli Lilly and Company; Forum Pharmaceuticals Inc.; Genentech, Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Neurocrine Biosciences Inc.; Otsuka America Pharmaceutical, Inc.; Pierre Fabre; Reviva Pharmaceuticals Inc.; Roche; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva. He is a shareholder of LB Pharmaceuticals Inc.; MedAvante Inc.; and Vanguard Research Group.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).